To evaluate the effect of clinical pathway (CP) in the therapeutic treatment hepatic alveolar echinococcosis (HAE).

The clinical data were analyzed retrospectively, including 84 patients in CP group and 86 patients in non-CP group. Statistical analysis was performed by using SPSS 19.0 software. Measurement data were expressed as mean±standard deviation and were examined by independent t test. Count data such as the incidence of postoperative complications were described by (n, %) and were examined by chi square test. The correlation between predicted resected liver volume and actual resected liver volume were also analyzed. A P value of <0.05 was considered as statistically significant.

The hospitalization time of (10.9±1.3) d and hospitalization expenses of (35±3) thousand yuan in the CP group were significantly lower than (14.1±1.2) d and (38±4) thousand yuan in the non-CP group respectively, P<0.05; The patient’s satisfaction in CP group was higher, and the knowledge of echinococcosis health at discharge was better than those in non-CP group respectively (P<0.05). There was no significant difference in the incidence of postoperative complications between the two groups (P>0.05).

Implementing the clinical pathway of HAE could effectively shorten the hospitalization time, reduce the cost of treatment as well as the economic burden of patients, and has a positive effect on improving patient satisfaction and popularizing the health knowledge of echinococcosis. It is worthy of clinical application and promotion, but the incidence of mutations in the clinical pathway is high, requiring timely intervention and continuous optimization management for clinical use.